Combining immunotherapy and epidermal growth factor receptor kinase inhibitors: worth the risk?.
- 2019
English
2305-5839
10.21037/atm.2019.03.6 [doi] atm-07-S3-S76 [pii] PMC6685870 [pmc]
IN PROCESS -- NOT YET INDEXED
Washington Cancer Institute
Comment
Editorial